Sugi Predict

Sugi Predict / Targets / PPP3CA

PPP3CA

Protein phosphatase 3 catalytic subunit alpha · Q08209 · PPP3CA on Sugi Atlas →

5,507 patent compounds predicted against PPP3CA, 4,952 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1387267 SCHEMBL1387267 1.00 12/20
SCHEMBL1387485 SCHEMBL1387485 0.89 12/20
SCHEMBL1387328 SCHEMBL1387328 0.85 12/20
SCHEMBL1387282 SCHEMBL1387282 0.85 12/20
SCHEMBL1387205 SCHEMBL1387205 0.83 12/20
SCHEMBL1387376 SCHEMBL1387376 0.74 12/20
SCHEMBL1388975 SCHEMBL1388975 0.74 12/20
SCHEMBL1387424 SCHEMBL1387424 0.73 12/20
SCHEMBL1387256 SCHEMBL1387256 1.00 11/20
SCHEMBL1388894 SCHEMBL1388894 0.88 11/20
SCHEMBL1387283 SCHEMBL1387283 0.87 11/20
SCHEMBL1387523 SCHEMBL1387523 0.85 11/20
SCHEMBL1387515 SCHEMBL1387515 0.85 11/20
SCHEMBL8921696 SCHEMBL8921696 0.80 11/20
SCHEMBL1387406 SCHEMBL1387406 0.76 11/20
SCHEMBL8916334 SCHEMBL8916334 0.65 11/20
SCHEMBL1387280 SCHEMBL1387280 0.93 10/20
SCHEMBL1387458 SCHEMBL1387458 0.93 10/20
SCHEMBL1387464 SCHEMBL1387464 0.91 10/20
SCHEMBL1387388 SCHEMBL1387388 0.88 10/20

Clinical trials — most relevant to PPP3CA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Open-label Study on Treatment of Primary Aldosteronism With Everolimus PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1/PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421 nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane nanUNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PPP3CA binder may also engage these)

ProteinNameSimilarity
P63328 — 1.000 P63328 →
P48452 — 1.000 P48452 →
P63329 — 1.000 P63329 →
P20651 — 0.996 P20651 →
P48453 — 0.995 P48453 →
PPP3CB Serine/threonine protein phosphatase PP2B-alpha catalytic subunit 0.992 landscape →
P48454 — 0.990 P48454 →
Q27889 — 0.956 Q27889 →
Q9VXF1 — 0.954 Q9VXF1 →
P48455 — 0.949 P48455 →
Q0IIZ2 — 0.940 Q0IIZ2 →
Q503E1 — 0.939 Q503E1 →
Q6GNQ1 — 0.937 Q6GNQ1 →
O54984 — 0.937 O54984 →
Q6IQE5 — 0.935 Q6IQE5 →
G3V9T7 — 0.933 G3V9T7 →
Q9DFS6 — 0.933 Q9DFS6 →
GNPDA1 Glucosamine-6-phosphate deaminase 1 0.933 landscape →
A5PJI5 — 0.932 A5PJI5 →
GET3 ATPase GET3 0.932 landscape →
P48597 — 0.931 P48597 →
A4IHW6 — 0.931 A4IHW6 →
A4FV08 — 0.931 A4FV08 →
P11157 — 0.930 P11157 →
DHX9 ATP-dependent RNA helicase A 0.929 landscape →
P17427 — 0.929 P17427 →
Q28141 — 0.928 Q28141 →
P18484 — 0.928 P18484 →
Q5R874 — 0.928 Q5R874 →
P62498 — 0.927 P62498 →